French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)

Inclusion Criteria:

• Signed informed consent form.

• Patient with moderate to severe AD according to the Investigator's judgment and

1. Patient eligible to systemic treatment as Atopic Dermatitis Control Tool (ADCT)more than or equal to (≥) 7 and/or use topical corticosteroids (TCS) more than (>) 90 gram (g)/month and/or TCS are not advisable.or

2. Patient currently under systemic treatment.

• Able to understand and complete study-related questionnaires.

Exclusion Criteria:

• Any condition that, in the opinion of the Investigator, may interfere with patient'sability to participate in the study, such as short life expectancy, substance abuse,severe cognitive impairment, or other comorbidities that can predictably prevent thepatient from adequately completing, as per routine care, the schedule of visits andassessments

• Patient receiving systemic therapy only for a disease other than AD.

• Patient participating in any interventional clinical trial at the time of enrolment.

• Patient is under tutorship or curatorship; patient under safeguard of justice ordeprived of his/her liberty by an administrative or court decision

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.